Response rates (RR) and median progression‐free survival (PFS) associated with EGFR TKI therapies among SqCC appear to be lower than among patients with adenocarcinoma, with 25% to 43.2% versus 54.4% to 80% for RR and 1.4–5.1 months versus 9–13 months for PFS, respectively.8, 18, 19, 20, 21 Some reports have argued that EGFR‐mutated SqCC have mixed ADC histology due to the diagnostic limitations of small biopsies and intratumoral heterogeneity. Here, EGFR is linked to adenocarcinoma.